Preclinical Evaluation of Completely Biological Monocusp Valve and Transannular Patch for the Fallot’s Tetralogy Correction – BIOVALVE

Fallot's tetralogy is the most common cyanotic heart malformation in newborns. It can be corrected by surgical management which consists in enlarging the right ventricular outflow tract. This approach generates pulmonary valve leakage that must be repair. Synthetic or chemically-treated biological patches from animals could be used to limit the leak. However, these patches have proven ineffective and have been associated with severe postoperative complications. We have developed a completely biological tissue without chemical treatment produced by human cells that can potentially grow with the patient. This project aims to study the applicability and the preclinical effectiveness of this biological tissue for the Fallot's tetralogy repair. Ultimately, this biological tissue could be an innovative and effective therapy solution for this pediatric population.